Welcome to our dedicated page for Kamada SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kamada Ltd (KMDA) SEC filings page on Stock Titan provides access to the company’s public reports as a foreign private issuer. Kamada files current reports on Form 6-K under the Securities Exchange Act of 1934, which include press releases, financial statements, presentations and other shareholder communications.
For Kamada, these filings are a primary source of information on its specialty plasma-derived therapies business, including proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Recent 6-Ks have attached quarterly and nine-month consolidated financial statements, discussions of revenues and adjusted EBITDA, and details on the performance of the Proprietary Products and Distribution segments.
Filings also document clinical and operational milestones, such as the discontinuation of the InnovAATe Phase 3 trial of Inhaled AAT following an interim futility analysis, the initiation of the investigator-initiated SHIELD study for CYTOGAM in kidney transplantation, and regulatory approvals for Kamada’s plasma collection center in Houston, Texas. Additional 6-Ks provide notices of annual general meetings, investor conference participation, and extensions of supply tenders, for example with Canadian Blood Services.
On Stock Titan, Kamada’s filings are updated as they are released to EDGAR, and AI-powered tools summarize key points from each document to help users interpret complex disclosures. Investors can review attached financial statements, presentations, and exhibits listed in the 6-K exhibit indexes, and track how Kamada reports on its growth pillars, plasma collection expansion, and business development activities over time.